Testing
RediTesting is capable of performing Nasopharyngeal swab (nasal swab) for a lab-based test to detect COVID-19. These test results require 3-5 business days for results and are looking for the DNA associated with the virus.
Please visit the CDC site for more information about COVID-19: https://www.cdc.gov/coronavirus/2019-ncov/index.html
Please call for an appointment for COVID-19 nasal swab testing.
Instant Screening
RediTesting is capable of conducting COVID-19 serology screens. This will screen for the presence of anti-bodies in the blood by using a finger-stick and drop of blood. This screen checks the blood for both immunoglobulin-G (IgG), and immunoglobulin-M (IgM).
Serology screening provides an instant result within 3-5 minutes through an easy and accurate point-of-care device. Per Vanderbilt University,
“What could a positive COVID-19 serology test tell us about a patient?
Current data suggest that IgM antibodies against SARS-CoV-2 develop in the circulation after the first week of COVID-19, while IgG antibodies become detectable sometime beyond 14 days of infection.
As a result, detection of specific antibodies (IgM, IgG, or both) against SARS-CoV-2 would suggest that a person has been infected with the virus at some time in the past.”
Due to the small size and portability of the device, these screens are particularly well suited for on-site/back-to-work programs, providing you on-the-spot information for your pandemic management program.
These screens are particularly well suited for on-site testing in remote locations, schools, businesses, oil/gas rigs, and government facilities.
RediTesting can arrange for this screening with your organization in San Antonio, across the country, or World-wide.
Video Links
Here are links to a couple short YouTube videos on the screening.
The overview: https://www.youtube.com/watch?v=EDRkkP_L08o&feature=youtu.be
The closeup of the process: https://www.youtube.com/watch?v=o21RaChcgCc&feature=youtu.be
Authorization
These screening devices are authorized for use for the duration of the Emergency Use Authorization (EAU) for SARS-CoV-2 Antibody tests. [Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1)]